U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07816250) titled 'A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naive Adults (CINERGY)' on Sept. 06.
Brief Summary: The purpose of this Phase 2b study is to evaluate the efficacy and therapeutic window of chronically dosed VH4011499 paired with an integrase strand transfer inhibitor (INSTI). This study will explore 4 different regimens of VH4011499 when paired with cabotegravir (CAB) as an initial two-drug regimen.
Study Start Date: Oct. 19
Study Type: INTERVENTIONAL
Condition:
HIV Infections
Intervention:
DRUG: VH4011499
Participants receive injectable VH4011499 at different dose...